DarshanTalks Podcast
by Darshan Kulkarni
Welcome to DarshanTalks! 152254 We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there! Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do. We focus on life science issues involving medical affairs, marketing and advertising, and clinical research so that you can learn about the industry, enhance your business and grow your career. 152254
Episodes
-
AI Drug Discovery: Who Owns the IP Rights?
Send us Fan Mail Episode Summary When an AI model designs a novel therapeutic molecule or predicts an enzyme structure, who legally owns the resulting intellectual property? In this episode of Darshan Talks / KF Deep Dive, host Darshan Kulkarni turns the microphone over to Stu Angus (Founder of...
-
Multi-State Non-Competes: The Site Network Template Trap
Send us Fan Mail Episode Summary: Can a clinical trial site network legally enforce a standardized, templated employment agreement containing restrictive covenants against a Principal Investigator (PI) across state lines? In this episode of the KF Deep Dive, host Darshan Kulkarni breaks down why...
-
100% HIPAA Compliant"? Why Your Badges Are Legal Debt
Send us Fan Mail Episode Summary: "We are 100% HIPAA compliant." If this claim sits on your clinical trial site, digital health app, or pharma landing page, you may be quietly accumulating catastrophic compliance debt. In this episode of the KF Deep Dive, host Darshan Kulkarni sits down with...
-
Decoding 340B: History, Legislative Styles, and Healthcare Policy with Deborah Williams
Send us Fan Mail Episode Overview: In this episode of KLF Deep Dive, host Darshan Kulkarni sits down with Deborah Williams, Founder of Health Policy Insights, LLC, to explore over three decades of healthcare policy evolution. Deborah brings a wealth of experience as a policy researcher, former...
-
Contrast Therapy: The Hidden Legal & Water Risks
Send us Fan Mail The wellness industry is undergoing a massive boom, but modern contrast therapy, thermal bathing, and sauna facilities are stepping directly into an unseen legal grid. In this episode of the Darshan Live podcast, host Darshan Kulkarni sits down with healthcare regulatory attorney...
-
BPC-157: The FDA Blacklist, PCAC Vote & Legal Exposure
Send us Fan Mail When podcast hosts and biohacking influencers promote "The Wolverine Stack"—coupling BPC-157 and TB-500 for rapid tissue and gut repair—it generates millions of dollars in consumer demand. But how does viral influencer marketing translate into real-world legal and regulatory…
more -
FDA Under Pressure: Enforcement, DOGE & Global Supply Chains
Send us Fan Mail What is happening inside the FDA, and how are regulatory shifts impacting pharmaceutical, medical device, and food companies? In this episode of the KLF Deep Dive, host Darshan Kulkarni sits down with veteran Food and Drug lawyer Alan Minsk (Partner and Chair of the Food & Drug...
-
Health Tech Startups: From Garage to FDA
Send us Fan Mail Thinking about launching a health tech startup, digital health app, or wearable device? Moving fast and breaking things might work in software, but in healthcare, breaking things means breaking people. In this episode of the KLF Deep Dive, host Darshan Kulkarni connects with…
more -
Is Your Clinical Trial IP Already Leaked?
Send us Fan Mail The wellness industry is undergoing a massive boom, but modern contrast therapy, thermal bathing, and sauna facilities are stepping directly into an unseen legal grid. In this episode of the KLF Deep Dive, host Darshan Kulkarni sits down with healthcare regulatory attorney Kate...
-
Decoding Australia's TGA Regulations
Send us Fan Mail Thinking about launching a health product, dietary supplement, or digital health solution in the Australian market? You might want to hit pause before assuming your U.S. or European regulatory strategy will translate. In this episode of the KLF Deep Dive, host Daran Carney…
more -
AI "Going Rogue": The Legality of Healthcare Chatbots
Send us Fan Mail What happens when an artificial intelligence chatbot moves past answering basic questions and starts actively pretending to be a licensed psychiatrist? In this episode of the KLF Deep Dive, host Daran Carney welcomes premier healthcare regulatory and privacy attorney Elizabeth...
-
Pharmacy's Critical Role in Clinical Trial Compliance
Send us Fan Mail Think clinical trial compliance is just a part-time job or a paperwork exercise that can be passed off to a medical assistant? Think again. In this episode of the KLF Deep Dive, host Daran Carney sits down with Tom Sepka, CEO of HCI Healthcare Consultants and veteran Chief…
more -
The Wild Lizard Venom Origins of Ozempic
Send us Fan Mail How a "Failed" 4-Minute Molecule Created a Trillion-Dollar Cultural Eclipse Imagine pitching a drug to a room of venture capitalists that is biologically perfect—except for one tiny flaw: the human body completely destroys it in four minutes flat. That is the exact garbage hand...
-
Unlicensed Medical Advice & The Legal Battle Over Character.AI
Send us Fan Mail What happens when an artificial intelligence chatbot generates a fake medical license number and starts giving psychiatric advice? In this episode of the KF Deep Dive, host Darshan welcomes healthcare regulatory expert and Fox Rothschild Chief Privacy Officer, Elizabeth Litten…
more -
Sponsoring Cannabis Research
Send us Fan Mail NOT LEGAL ADVICE For decades, cannabis research in the U.S. was stifled by Schedule I restrictions, requiring high-security vaults, mountains of paperwork, and extremely limited supply chains. With Executive Order 14370, the landscape has shifted. Marijuana is moving to Schedule...
-
The New Era of Personal Consent Decrees
Send us Fan Mail Is your career protected from your company’s mistakes? For decades, a Federal Consent Decree was a corporate headache. Today, it’s a personal professional death sentence. In this episode, Darshan Kulkarni breaks down the seismic shift in federal enforcement: why agencies are now...
-
Why Private Membership Associations Fail FDA Scrutiny
Send us Fan Mail In this episode of the KLF Deep Dive, Darshan Kulkarni deconstructs a persistent and dangerous myth circulating in life sciences and investment circles: the Private Membership Association (PMA). While often marketed as a "contract-based loophole" to evade FDA oversight and civil...
-
The Hidden Reason Sites are Firing Recruiters
Send us Fan Mail What would happen if your clinical trial sites were suddenly banned from using you? In this episode, Darshan Kulkarni uncovers a hidden regulatory shift: state licensing boards are tightening the "Corporate Practice of Medicine" and "Fee Splitting" laws. If your recruitment fees...
-
Don’t Let Your PI Walk Away With Your Study
Send us Fan Mail In this tactical masterclass, Darshan Kulkarni breaks down the critical legal architecture required to protect clinical trial sites during rapid expansion. As PIs and Sub-Investigators move between organizations, the risk of losing proprietary data and patient continuity...
-
Safe or Just "Not Dirty"? The Regulatory Gamble of Compounded Drugs
Send us Fan Mail In this episode, Darshan Kulkarni breaks down the staggering legal difference between the branded drugs you know (like Mounjaro) and the compounded versions flooding the market. Using a brilliant "Coke vs. RC Cola" analogy, we explore why "clean vats" aren't the same as "proven...
-
"Basically Employees" Isn't a Legal Category (And the OIG Knows It)
Send us Fan Mail Stop playing compliance theater. In this episode, Darshan Kulkarni pulls back the curtain on a dangerous trend in the life sciences: the over-reliance on contract sales forces without the legal control to back them up. Many companies believe they’ve "solved" the incentive pay...
-
The Hidden Legal Risks of AI Sponsor Protocols
Send us Fan Mail Is AI the savior of clinical research costs, or a ticking time bomb for data integrity? In this episode, Darshan Kulkarni dives into the murky waters of AI-driven sponsor protocols. We explore how AI is being used to mask—and unmask—data falsification, and what life science...
-
The $100M Mistake: Why AI-Generated Drugs May Not Be Patentable
Send us Fan Mail "The model said so" is not a defense. In the rush to integrate AI into drug discovery, life science companies are sprinting toward a compliance cliff. In this episode, Darshan Kulkarni—pharmacist and FDA regulatory lawyer—strips away the marketing hype to reveal the "messy…
more -
Is AI replacing your Doctor?
Send us Fan Mail In this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni explores the unsettling transition from "Googling your symptoms" to "Chatting with your symptoms." It’s 10:47 PM—you have chest tightness and a chatbot is your only companion. But is the algorithm...
-
Why the OIG Just Revolutionized Pharma Marketing (And What It Costs You)
Send us Fan Mail On January 27, 2026, the HHS Office of Inspector General (OIG) changed the game for pharmaceutical manufacturers. In a landmark Special Advisory Bulletin, the government officially opened a "green lane" for direct-to-patient (DTP) drug sales, specifically addressing the rise of...
-
6 Categories of "Bulk Data" That Could Land You in Federal Court.
Send us Fan Mail The DOJ just changed the rules of the game for the Life Sciences industry. As of January 2025, transferring "Bulk Sensitive Personal Data" to countries of concern—specifically China—is no longer just a compliance hurdle; it’s a potential federal violation. In this episode…
more -
The Utah Experiment: The Dangerous New Frontier of AI Prescribing
Send us Fan Mail Is your state "sandbox" a playground or a legal minefield? In this episode, Darshan Kulkarni—pharmacist and attorney—dissects the quiet movement of states like Utah allowing AI to manage and renew prescriptions. While the innovation is exciting, the federal government is watching...
-
Is Your DTC Program a Kickback Trap?
Send us Fan Mail The OIG has officially shifted the goalposts for Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) programs. For years, federal healthcare discounts were a "no-go zone," but a new dual-track strategy is emerging—if you know how to build the firewall. In this episode, Darshan...
-
The Hidden Death Sentence for Trial Sites
Send us Fan Mail In this episode of KLF Deep Dive, Darshan Kulkarni uncovers the catastrophic risks clinical trial sites face when they fail to vet their staff against federal exclusion lists. We move beyond simple compliance to discuss the "off-the-books" penalties that can end a career or a...
-
FDA "Screams": The Real Reason Your Snack Is At Risk
Send us Fan Mail Undeclared allergens remain the #1 cause of food recalls in the U.S., yet many brands still treat labeling as a "marketing" task rather than a "legal" one. In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the regulatory horror stories of major brands—from Nugo to...
-
2 Laws More Dangerous Than HIPAA for Patient Engagement
Send us Fan Mail Think HIPAA is your biggest hurdle in pharma marketing? Think again. In this episode of KLF Deep Dive, Darshan Kulkarni reveals why focusing solely on HIPAA leaves a massive, unregulated gap in your compliance strategy. We break down the "layered system" of risk—from aggressive...
-
"Invite-Only" Compliance Is Over: Is Your Cosmetic Company Ready?
Send us Fan Mail The "handshake" era of cosmetic compliance is officially over. Under new authorities in Sections 605, 610, and 704, the FDA has moved from simple observation to an aggressive "access and copy" mandate. In this episode, Darshan Kulkarni breaks down the "SAHCOD" threat and explains...
-
Audit-Proof Your Site: The Training Gap Killing Your Contracts
Send us Fan Mail In clinical research, if it isn't documented, it never happened. Many site owners mistake a competent team for a compliant one—a mistake that leads to disastrous FDA inspections and lost sponsor contracts. In this KLF Deep Dive, Darshan Kulkarni reveals the specific training…
more -
15 Years in Prison for Marketing Fraud
Send us Fan Mail Is your marketing team building a brand or a federal case? In this episode, we deconstruct the $1.2 billion collapse of Boom Care. What looked like a runaway success story in the wound care space was actually a systematic violation of the False Claims Act. We break down the three...
-
Is your "Clinical Decision Support" tool actually an unregulated medical device?
Send us Fan Mail In January 2026, the FDA sharpened the line between helpful software and regulated medical devices. If your AI sits inside an EHR, providing "black box" recommendations that a clinician can’t independently verify in seconds, you aren't just drifting into a regulatory gray area,...
-
The FDA’s New Political Enforcement Strategy
Send us Fan Mail In this episode, Darshan Kulkarni exposes a massive legal shift that is quietly dismantling the "Practice of Medicine" defense. We track the whiplash from the 2021 Ivermectin court victories to the DOJ’s aggressive 2025 memorandum targeting gender-affirming care. Is "Intended…
more -
Why Your "Physician-Only" Ads Aren't Safe from Regulators
Send us Fan Mail In this episode of the KLF Deep Dive, Darshan Kulkarni sits down with Phyllis Marcus, Vice President of the National Advertising Division (NAD) and former FTC veteran. They unpack the complex "grey area" where healthcare professional (HCP) communications bleed into the public...
-
The Messy Reality of AI Prescriptions
Send us Fan Mail State governments are racing to innovate by allowing AI to renew and improve prescriptions—but are they walking into a federal trap? In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the "Utah Sandbox" model and the three massive warning signs flashing for the life...
-
Why Your Consultant’s Report Is a Legal Liability
Send us Fan Mail In the high-stakes world of Life Science M&A, hiring expert consultants for GXP, IT, and data privacy is standard operating procedure. But there is a hidden structural flaw in most due diligence programs: Scope Creep. When a consultant identifies "high risk" in a data transfer...
-
Stop Reporting Results? The NIH’s "Get Out of Jail Free" Card
Send us Fan Mail The NIH just dropped a regulatory bombshell: Notice NOT-OD-26-032. Effectively immediately, Basic Experimental Studies in Humans (BESH) are no longer classified as "Clinical Trials" for reporting purposes. Is this a victory for common sense, or an administrative "fudge" to hide...
-
Final LGBTQ Individuals in clinical research
Send us Fan Mail Support the show www.kulkarnilawfirm.com
-
When the FDA Plays Politics
Send us Fan Mail In this episode of KLF Deep Dive, we examine a chilling shift in regulatory enforcement: the weaponization of "Intended Use." If the science hasn't changed and the law hasn't changed, why is the FDA pivoting from "advice-giving" to "subpoena-swinging"? Host Darshan Kulkarni…
more -
Your Site’s Background Check is Illegally Incomplete - Here is why
Send us Fan Mail In this episode, Darshan Kulkarni dives into the terrifying reality of compliance failures at clinical trial sites. While most directors worry about standard fines, the true danger lies in the "off-the-book" penalties and the looming threat of criminal prosecution for employing...
-
Is Your Off-Label Use Now a Federal Crime?
Send us Fan Mail For decades, a "clean mental line" existed: Doctors prescribe, and companies don't promote off-label. That line just got a lot messier. In this episode, Darshan Kulkarni breaks down the Hsaio Declaration—a seismic shift in DOJ enforcement that aims to turn independent medical...
-
10,000 Specialists: A Futurist’s Vision for AI Healthcare
Send us Fan Mail In this episode, we sit down with world-renowned futurist Bruce McCabe to cut through the hype of large language models like ChatGPT and explore the "stunningly optimistic" reality of Specialist (Narrow) AI. Bruce shares insights from his global travels to research labs…
more -
The Battle Over Weight Loss and Compounded Drugs
Send us Fan Mail In this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni deconstructs the legal "scorched-earth" offensive currently reshaping the weight loss drug industry. Following the February 2026 announcement that the GLP-1 shortage is officially resolved, the "Golden...
-
Why Cosmetic Ingredient Names Matter and What MOCRA Really Means - Interview with Heather Bustos
Send us Fan Mail In this episode, I sit down with FDA compliance attorney Heather Butos to unpack two topics most cosmetic pros ignore until it’s too late: INCI (ingredient) names and MOCRA (the new cosmetic law). We talk about how ingredient naming is not just labeling, it’s a strategic business...
-
Compliance Isn’t a Deal Killer… Until It Is - Interview with Stephanie Trunk
Send us Fan Mail Life sciences M&A is picking up again, but today’s deals look nothing like they did two years ago. In this episode, Darshan Kulkarni sits down with Stephanie Trunk, Partner at ArentFox Schiff, to unpack what’s really driving renewed deal activity and what buyers are still missing...
-
Cosmetic ingredients the FDA doesn’t want you to use
Send us Fan Mail A brief discussion on the various cosmetic ingredients used by cosmetic manufacturers and the concerns FDA has recently found as a result of their own study into the process Support the show www.kulkarnilawfirm.com
-
Why Federal Agencies Are Targeting Executives
Send us Fan Mail Federal enforcement is changing. Regulators aren’t just going after companies anymore. They’re naming CEOs, CMOs, heads of clinical, quality, and operations in consent decrees and injunctions. Once your name is on that document, it follows you for years and shapes your career. In...
About this show
Welcome to DarshanTalks! 152254
We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there!
Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do.
We focus on life science issues involving medical affairs, marketing and advertising, and clinical research so that you can learn about the industry, enhance your business and grow your career.
152254
Hosted by
Darshan Kulkarni